Stay updated with breaking news from Michael Tusche. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
NEW YORK, Feb. 3, 2023 /PRNewswire/ -- Treadwell Therapeutics, a clinical-stage, global biotechnology company developing novel, first in class therapeutics for highly aggressive cancers, today
/PRNewswire/ -- Treadwell Therapeutics, a clinical-stage biotechnology company developing novel, small molecule therapeutics for highly aggressive cancers,...
/PRNewswire/ -- Treadwell Therapeutics, a clinical-stage biotechnology company developing novel medicines for highly aggressive cancers, today announced that...
NEW YORK and HONG KONG, June 14, 2022 /PRNewswire/ -- Treadwell Therapeutics, a clinical-stage biotechnology company developing novel medicines for unmet needs in cancer, today announced the initiation of patient dosing in TWT-203, its Phase 1b/2 study to evaluate CFI-402257, an oral, best-in-class inhibitor of Threonine Tyrosine Kinase (TTK, also known as MPS1) in patients with advanced solid tumors and ER+/Her2- breast cancer. Dosing of the first patient in the trial commenced June 8that START Mountain Region in Salt Lake City, Utah. "Inhibition of TTK, a key mitotic checkpoint, with CF...
/PRNewswire/ -- Treadwell Therapeutics, a clinical-stage biotechnology company developing novel medicines for unmet needs in cancer, today announced the...